- Conditions
- Renal Cell Carcinoma
- Interventions
- Intismeran autogene, Pembrolizumab, Placebo
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 1,620
matching trials from the local directory fallback.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Head and Neck Cancers, NSCLC, Ovarian Cancer, Prostate Cancer
- Interventions
- IDE-161, Pembrolizumab
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Gaucher's Disease Type III
- Interventions
- Venglustat, imiglucerase
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Iowa City, Iowa • Dallas, Texas + 1 more
- Conditions
- Solid Tumor, Adult
- Interventions
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Drug · Biological
- Lead sponsor
- Linnaeus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Inotuzumab Ozogamicin, Mercaptopurine, Methotrexate, Methylprednisolone, Prednisone, Rituximab, Vincristine
- Drug · Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Irvine, California • Orange, California + 60 more
- Conditions
- Gaucher Disease Type 1, Gaucher Disease Type 3
- Interventions
- imiglucerase, venglustat (GZ402671)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Dallas, Texas • Fairfax, Virginia
- Conditions
- Drug Interaction, Obesity, Overweight, Overweight and/or Obesity
- Interventions
- Acetaminophen, PF-08653944
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Myelofibrosis
- Interventions
- Best Available Therapy (BAT), Imetelstat
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • New Haven, Connecticut + 9 more
- Conditions
- Colo-rectal Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma
- Interventions
- Cemiplimab, VV1
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 429
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- CC-99282, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Epcoritamab, Ibrutinib, Lenalidomide, Polatuzumab Vedotin, Prednisone, Rituximab
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
- Conditions
- Leukemia
- Interventions
- Chemotherapy, Placebo, Quizartinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 52
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 275
- States / cities
- Birmingham, Alabama • Clovis, California • Concord, California + 195 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1403
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
- Conditions
- Breast Cancer
- Interventions
- No Radiation, Radiation
- Other · Radiation
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 2,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 451
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
- Conditions
- Locally Advanced Breast Cancer, Metastatic Triple Negative Breast Cancers, Triple Negative Breast Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), BNT327 Equivalent Q3W Dose, BNT327 Optimized Dose, Carboplatin, Eribulin, Gemcitabine, Nab-placlitaxel, Paclitaxel
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Epoetin Alfa, Luspatercept
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 33
- States / cities
- Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- AVF, Acellular Tissue Engineered Vessel (ATEV)
- Other · Biological
- Lead sponsor
- Humacyte, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more
- Conditions
- Normal Pressure Hydrocephalus
- Interventions
- CereVasc eShunt System, VP Shunt
- Device
- Lead sponsor
- CereVasc Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more
- Conditions
- Severe Aortic Stenosis
- Interventions
- Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI), Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
- Device · Procedure
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
- Conditions
- Decision Aid, Geriatrics, Mammography Screening
- Interventions
- Video based decision aid, Written decision aid
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 75 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Kidney Cancer, Renal Cancer, Tumor, Tumor, Benign, Tumor, Solid
- Interventions
- HistoSonics Edison System
- Device
- Lead sponsor
- HistoSonics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- ABBV-969
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more